PLA2G6 and Parkinson disease: Here we report a comprehensive serological metabolomic profiling using a well-characterized cohort of PLA2G6-associated young-onset dystonia–parkinsonism patients and matched controls with the aim to describe metabolic features and identify potential biomarkers for the PLA2G6 mutations and severity of clinical symptoms.